Cerulean Pharma (CERU) shares have surged in trading today after the company announced that the FDA has designated its lead nanoparticle-drug conjugate, Phase 1/2-stage CRLX101, for Fast Track review for the treatment of platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.